KYKymera Therapeutics KYMR · NASDAQ
$108.07 +3.14% (+$3.29)
- Market cap
- $8.89B
- Enterprise value
- $8.85B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 84.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -22.0%
- Bruto marža
- 102.0%
- Neto marža
- -285.4%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 1.98
- Free float
- 80.3%
O podjetju
Kymera Therapeutics is a U.S.-based biotechnology company that specializes in the development of therapeutics aimed at protein modulation using advanced protein degradation technologies. The company uses an innovative approach to treating diseases by focusing on selectively degrading faulty proteins in the body rather than blocking them. Kymera Therapeutics focuses on developing drugs for the treatment of oncology, immunology, and rare diseases, with its technology holding the potential to significantly change the way many serious health issues are treated.
Sector
Healthcare
Industry
Biotechnology
CEO
Nello Mainolfi
Employees
273
Headquarters
Watertown
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke